Imunon reports Q2 2026 results, cites OVATION 3 enrollment pace and new MRD data
The company said enrollment in its Phase 3 ovarian cancer trial is running ahead of plan, with cash of $6.9 million as of June 30, 2026.
IMUNON, Inc. reported financial results for the second quarter of 2026 on August 11, 2026, alongside updates on its lead candidate IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer. IMNN-001 has completed a Phase 2 trial (OVATION 2) and is currently in the Phase 3 OVATION 3 trial, with the first patient dosed in the third quarter of 2025.1 The company said enrollment in OVATION 3 continues to exceed its planning assumptions.1
On June 23, 2026, an independent Data Monitoring Committee recommended that the pivotal Phase 3 OVATION 3 trial continue, evaluating IMNN-001 combined with standard of care neoadjuvant and adjuvant chemotherapy.1 On July 30, 2026, the company provided a trial progress update, saying it has seen rapid site activation and enrollment exceeding its forecast since the trial began.1 It reported that the trial moved from protocol submission to site activation in about 6 months and from protocol approval to first patient randomized in about 2 months, which it said was a third of the external industry benchmark timeline.1
On July 21, 2026, the company disclosed early results from an ongoing Phase 2 minimal residual disease study. Nine patients in each arm had reached second-look laparoscopy, the study's primary MRD assessment point, and preliminary data showed a lower MRD-positive rate in the IMNN-001 arm (44% vs. 67%), higher circulating tumor DNA clearance (87.5% vs. 62.5%), and a higher rate of no evidence of disease after frontline therapy (100% vs. 56%).1
On corporate developments, on June 4, 2026 the company entered definitive agreements for $10 million in gross proceeds, including 250 shares of preferred stock for $2.5 million and two secured promissory notes of $2.72 million and $5.0 million bearing 8% and 5% annual interest, maturing 18 months after issuance.1
As of June 30, 2026, cash and cash equivalents were $6.9 million.1 Net cash used in operating activities for the first half of 2026 was $7.0 million, up from $5.8 million a year earlier, mainly reflecting OVATION 3 trial expenses.1 The company plans an R&D Day on September 23, 2026 in New York featuring clinical investigators discussing IMNN-001 and its DNA-mediated immunotherapy platform.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.